Systemic sclerosis (Scleroderma)

Acta Clinica Belgica

Volumn 62, Issue 5, 2007, Pages 323-329

  Roufosse, Florence E ^a,b   De Bellefon, L M ^a  

^a UNIVERSITÉ LIBRE DE BRUXELLES   (Belgium)

^b ERASME HOSPITAL   (Belgium)

Author keywords

Fibrosis; Imatinib; Rituximab; Stem cell transplantation; Systemic sclerosis; TGF beta

Indexed keywords

ATORVASTATIN; AUTOANTIBODY; COLLAGEN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IMATINIB; RITUXIMAB; TRANSFORMING GROWTH FACTOR BETA;

COMPREHENSION; CONFERENCE PAPER; DISEASE COURSE; EXTRACELLULAR MATRIX; INTERVENTION STUDY; MICROANGIOPATHY; NONHUMAN; PATHOLOGY; PROGNOSIS; SCLERODERMA; SYSTEMIC SCLEROSIS;

ANIMALS; AUTOIMMUNITY; DISEASE PROGRESSION; FIBROSIS; HUMANS; IMMUNOLOGIC FACTORS; LYMPHOCYTE ACTIVATION; PROGNOSIS; SCLERODERMA, SYSTEMIC; STEM CELL TRANSPLANTATION;

EID: 37149022796     PISSN: 00015512     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (31)

1. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum 1980; 23: 581-90.
2. LeRoy EC, Medsger TA, Jr. Criteria for the classification of early systemic sclerosis. J Rheumatol 2001; 28: 1573-6.
3. LeRoy EC, Black C, Fleischmajer R et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol 1988; 15: 202-5.
4. Mayes MD, Lacey JV, Jr., Beebe-Dimmer J et al. Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum 2003; 48: 2246-55.
5. Trad S, Amoura Z, Beigelman C et al. Pulmonary arterial hypertension is a major mortality factor in diffuse systemic sclerosis, independent of interstitial lung disease. Arthritis Rheum 2006; 54: 184-91.
6. Ferri C, Valentini G, Cozzi F et al. Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients. Medicine (Baltimore) 2002; 81: 139-53.
7. Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis 2007; 66: 940-4.
8. Abraham DJ, Varga J. Scleroderma: from cell and molecular mechanisms to disease models. Trends Immunol 2005; 26: 587-95.
9. LeRoy EC. Systemic sclerosis. A vascular perspective. Rheum Dis Clin North Am 1996; 22: 675-94.
10. Charles C, Clements P, Furst DE. Systemic sclerosis: hypothesis-driven treatment strategies. Lancet 2006; 367: 1683-91.
11. Varga J, Abraham D. Systemic sclerosis: a prototypic multisystem fibrotic disorder. J Clin Invest 2007; 117: 557-67.
12. Baroni SS, Santillo M, Bevilacqua F et al. Stimulatory autoantibodies to the PDGF receptor in systemic sclerosis. N Engl J Med 2006; 354: 2667-76.
13. Denton CP, Merkel PA, Furst DE et al. Recombinant human antitransforming growth factor beta1 antibody therapy in systemic sclerosis: a multicenter, randomized, placebo-controlled phase I/II trial of CAT-192. Arthritis Rheum 2007; 56: 323-33.
14. Kerkela R, Grazette L, Yacobi R et al. Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 2006; 12: 908-16.
15. Distler JH, Jungel A, Huber LC et al. Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis. Arthritis Rheum 2007; 56: 311-22.
16. Ghofrani HA, Seeger W, Grimminger F. Imatinib for the treatment of pulmonary arterial hypertension. N Engl J Med 2005; 353: 1412-3.
17. Del Papa N, Quirici N, Soligo D et al. Bone marrow endothelial progenitors are defective in systemic sclerosis. Arthritis Rheum 2006; 54: 2605-15.
18. Kuwana M, Kaburaki J, Okazaki Y, Yasuoka H, Kawakami Y, Ikeda Y. Increase in circulating endothelial precursors by atorvastatin in patients with systemic sclerosis. Arthritis Rheum 2006; 54: 1946-51.
19. Derk CT, Jimenez SA. Statins and the vasculopathy of systemic sclerosis: potential therapeutic agents? Autoimmun Rev 2006; 5: 25-32.
20. Furukawa S, Yasuda S, Amengual O, Horita T, Atsumi T, Koike T. Protective effect of pravastatin on vascular endothelium in patients with systemic sclerosis: a pilot study. Ann Rheum Dis 2006; 65: 1118-20.
21. Sato S, Fujimoto M, Hasegawa M, Takehara K, Tedder TF. Altered B lymphocyte function induces systemic autoimmunity in systemic sclerosis. Mol Immunol 2004; 41: 1123-33.
22. Sakkas LI, Xu B, Artlett CM, Lu S, Jimenez SA, Platsoucas CD. Oligoclonal T cell expansion in the skin of patients with systemic sclerosis. J Immunol 2002; 168: 3649-59.
23. Nelson JL, Furst DE, Maloney S et al. Microchimerism and HLA-compatible relationships of pregnancy in scleroderma. Lancet 1998; 351: 559-62.
24. Evans PC, Lambert N, Maloney S, Furst DE, Moore JM, Nelson JL. Long-term fetal microchimerism in peripheral blood mononuclear cell subsets in healthy women and women with scleroderma. Blood 1999; 93: 2033-7.
25. Lambert NC, Erickson TD, Yan Z et al. Quantification of maternal microchimerism by HLA-specific real-time polymerase chain reaction: studies of healthy women and women with scleroderma. Arthritis Rheum 2004; 50: 906-14.
26. Maloney S, Smith A, Furst DE et al. Microchimerism of maternal origin persists into adult life. J Clin Invest 1999; 104: 41-7.
27. Tashkin DP, Elashoff R, Clements PJ et al. Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med 2006; 354: 2655-66.
28. Vanthuyne M, Blockmans D, Westhovens R et al. A pilot study of mycophenolate mofetil combined to intravenous methylprednisolone pulses and oral low-dose glucocorticoids in severe early systemic sclerosis. Clin Exp Rheumatol 2007; 25: 287-92.
29. Ratanatharathorn V, Ayash L, Reynolds C et al. Treatment of chronic graft-versus-host disease with anti-CD20 chimeric monoclonal antibody. Biol Blood Marrow Transplant 2003; 9: 505-11.
30. Cutler C, Miklos D, Kim HT et al. Rituximab for steroid-refractory chronic graft-versus-host disease. Blood 2006; 108: 756-62.
31. Farge D, Passweg J, van Laar JM et al. Autologous stem cell transplantation in the treatment of systemic sclerosis: report from the EBMT/EULAR Registry. Ann Rheum Dis 2004; 63: 974-81.